HIGHLIGHTS
- who: Christina Woopen from the Heinrich Heine University of Düsseldorf, Germany have published the Article: Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses, in the Journal: (JOURNAL) of 22/02/2021
- what: An interim analysis of this trial showed that treatment with sotrovimab led to a significant risk reduction for hospitalization and death in comparison to placebo .
SUMMARY
Selected immunomodulatory agents like sphingosine-1-phosphate receptor (S1PR) modulators and anti-CD20 treatment limit the patients' ability to mount sufficient . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.